FDA grants orphan drug designation to HLX22 for gastric cancer, with a phase 2 trial showing improved progression-free ...

Drs Ursula A. Matulonis and Gini F. Fleming discuss the state of endometrial cancer, the role of immunotherapy, and priorities for research in this field.

Phesgo comes in a single-dose vial and can be dosed as a subcutaneous injection, while at the moment breast cancer patients the two anti-HER2 drugs separately receive Herceptin as a subcutaneous ...

Enhertu consists of the antibody used in Roche’s blockbuster HER2 antibody Herceptin (trastuzumab), linked to a topoisomerase inhibitor that is toxic to cancer cells. Around one in five patients ...

HLX22 is an anti-HER2 monoclonal antibody (mAb). A multicenter ... and plans to evaluate the efficacy and safety of HLX22 when given in combination with trastuzumab (Herceptin) and chemotherapy as a ...

Targeted treatments like Roche’s trastuzumab (Herceptin) have transformed outcomes for patients ... The candidate in question is a bispecific antibody called BNT327 that targets both PD-L1 and VEGF-A.

Research has shed light on how a new type of antibody treatment reactivates patients' immune cells to fight ovarian cancer.

Research has shed light on how a new type of antibody treatment reactivates patients' immune cells to fight ovarian cancer.

A recent study published in Science Translational Medicine involving scientists from the U.S. Army Medical Research Institute ...